NewsRoom Articles - Page 91 of 214

TuesdayNov 29, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

A growing chorus of concerns about brain concussions resulting from athletic events is helping to propel new interest in developing pharmaceuticals to treat this “unmet medical need” Concussion treatments have largely focused on simple rest, but medical product developer Odyssey Health Inc. is developing a potential treatment to reduce brain inflammation so needed therapy can get to the site of a brain injury Odyssey is also developing solutions for other central nervous system troubles, such as the highly fatal childhood disease Niemann-Pick type C, and nerve gas exposure sickness The neuropharmaceutical market is forecast to have a great deal of…

TuesdayNov 29, 2022 10:12 am

Four Facts You Need to Know About Brain Cancer

Brain cancer is one of the most debilitating conditions on the planet. Affecting an estimated 700,000 Americans, the condition has no cure and is often associated with poor negative outcomes, especially when diagnosed late. The main treatment options for brain cancer are surgery, chemotherapy and radiation, and the treatments tend to be more effective if the tumor is spotted and addressed in the early stages. Overall, brain tumors terrify most people because they can grow right under your nose and are often diagnosed when it is too late. RUSH chief of Medical Neuro-Oncology Seam Grimm, MD, recently discussed some of…

MondayNov 28, 2022 9:46 am

Type 2 Diabetes Patients Are Diagnosed Late If They Develop Cancer

Early diagnosis is critical for positive outcomes in cancer. Although there is no effective cure for cancer, early diagnosis allows physicians to deploy treatments such as surgery, radiation and chemotherapy that can reduce the size of the tumor and increase life expectancy. Research shows that nearly one-half of people who develop cancer are diagnosed late, reducing the chances of successful treatment and limiting their survival chances. A recent study by postdoctoral researcher Dr. Anna Jansana has revealed that people with type 2 diabetes are more likely to receive late diagnoses if they develop a type of cancer that isn’t screened…

MondayNov 28, 2022 9:06 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastoma CNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in France CNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patients The company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has…

WednesdayNov 23, 2022 11:15 am

MetAlert Inc. (MLRT) Is ‘One to Watch’

MetAlert’s management team is highly experienced (several previous exits) in the tech, apparel, and wearable medical device industries, with significant management ownership (70%+) in MLRT The company operates in a large and growing global market in terms of potential revenue ($20-$50+ per month) and number of users (34+ million), with a potential impact on hundreds of millions The recent pandemic created an emphasis on health monitoring, especially for at-risk consumers/patients The recent pandemic negatively impacted the supply chain and shipping, creating a backlog of orders, but recent months’ activity suggests that the supply chain and shipping issues will be resolved…

WednesdayNov 23, 2022 10:11 am

Department of Defense Awards Scientists at University of Buffalo $4M Grant to Study Concussion Treatment

For quite a while, experts have described concussions and traumatic brain injuries as a “silent epidemic” affecting millions across America. Concussions usually occur when an indirect or direct blow to an individual’s head causes their brain to slam against the inside of their skull and sustain damage. These injuries can be hard to treat because they usually don’t display symptoms at the time of injury. In some cases, symptoms can take days or even weeks to manifest, and it is often the victim's family and friends who notice changes in personality first, such as mood swings, irritability, anger and general…

WednesdayNov 23, 2022 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer

New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help…

TuesdayNov 22, 2022 11:50 am

World Cup 2022 to Feature New Protocol to Respond to Suspected Concussions

Now that the 2022 World Cup is upon us, FIFA officials have issued a safety protocol that would guide medics on how to respond to suspected concussions. Injuries are not uncommon in football, a highly physical sport that requires an impressive degree of physicality and often pushes players to the edge. And, unlike American football players who are usually decked out in hard protection, football players don’t wear any protection apart from shin guards. Critically, football players do not wear any head protection, exposing their heads to direct blows at relatively high velocities. During the finals of the 2014 World…

TuesdayNov 22, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Director of Communications and Investor Relations Presents at LD Micro Main Event

BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumors CNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBM Berubicin is a novel anthracycline and the first to appear to cross the blood-brain barrier The global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP),…